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ABSTRACT 
 
Objective: The objective of this study is to examine the association between initiating 
antihypertensive medications and bone mineral density (BMD) loss over time in women while 
transitioning through menopause. 
Methods: Women who initiated antihypertensive use during menopausal transition were selected 
from the Study of Women across the Nation. Nonusers were matched to users with two methods: 
frequency matching and propensity score matching. Femoral neck, total hip and lumbar spine 
BMD were assessed annually and rate of loss was calculated and used as outcomes. Mixed-
effects regression modeling strategy was used to examine the association between 
antihypertensive use and BMD loss. 
Results: Among 2365 eligible women, we identified new users of angiotensin-converting 
enzyme inhibitors (ACE), beta blocker, and thiazide diuretics (N= 98, 107, and 99, respectively) 
and frequency-matched nonusers (N=1001). After propensity score matched sets were created, 
69 ACE, 88 beta blocker and 76 thiazide users were matched with equal numbers of nonusers. 
After adjustment for potential confounders, both methods show that thiazide diuretics have a 
protective effect on femoral neck, total hip and lumbar annualized BMD loss compared to 
nonusers. Neither ACE nor beta blocker has an association with BMD loss at any anatomic site. 
Marnie Bertolet, Ph.D. 
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After matched using propensity scores, it shows that thiazide has a significantly protective effect 
on lumbar spine during late- and post- menopause, but not during pre- /peri-menopause. 
Conclusion: In this cohort of women across the menopausal transition, use of thiazide diuretics 
is associated with a decreased rate of bone loss at the lumbar spine, total hip and femoral neck 
and use of ACE or beta blocker is not associated with bone loss at any of the sites. 
Public Health Significance: The findings in this study provided reassurance for women who 
were using ACE or beta blocker to control blood pressure during the menopause transition, 
because neither of them has any negative effect on BMD loss during the transition. The results of 
this study also encourage clinicians to integrate the benefits of using thiazide diuretics, from the 
prospective of protecting the bone loss, into patients’ education, especially for women during 
late- or post-menopause if there are no other contraindications.  
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 1 
1.0  INTRODUCTION 
Approximately 6,000 women reach menopause every day (over 2 million per year) in the United 
States.
1
  Women’s health, especially bone health, is critical during this transition phase because 
research shows that bone mineral density (BMD) loss begins before the cessation of menses, 
accelerates 1 year before the final menstrual period (FMP) and slows 2 years after it.
2
 
Approximately one in two women over age 50 will break a bone because of osteoporosis.
3
  
Osteoporosis is defined as a disease characterized by low bone mass and deterioration of 
bone structure, causing bone fragility and increased risk of fracture. According to the statistics 
provided by the National Osteoporosis Foundation, about 80% of the estimated 10 million 
Americans with osteoporosis, are women.
3
 Moreover, osteoporosis and hypertension share a 
similar etiopathology and often coexist.
4
 Since the 1960s, antihypertensive medications have 
been discovered and are increasingly and regularly used among patients. Assessing the 
relationship between exposure to antihypertensive medications and BMD loss is essential for 
people who are diagnosed as hypertensive and at risk for osteoporosis, especially for women 
during the menopausal transition. 
The Study of Women’s Health Across the Nation (SWAN) is a multiethnic, multicenter, 
longitudinal community-based cohort study of the psychosocial and biological changes that 
occur during the menopausal transition.
5
 The bone data from the SWAN study was obtained 
annually from five study sites (Boston, Pittsburgh, Detroit, Oakland, and Los Angeles areas) 
 2 
among the 7 sites in SWAN, allowing for research on women during the menopause transition 
period. The aim of this secondary analysis is, distinguished from previous research, to investigate 
the effect of initiating antihypertensive medications on BMD loss, with a focus on 
transmenopause. This analysis will quantify the effect of antihypertensive medications exposure 
during the transition on bone health and will help healthcare professionals incorporate 
knowledge of antihypertensive medications into treatment and patient education. 
1.1 SWAN STUDY 
SWAN, first funded since 1994, is sponsored by the National Institute on Aging and the National 
Institute of Nursing Research.
6
 This study has 7 clinical field sites in the United States, including 
Detroit, MI (University of Michigan), Boston, MA (Massachusetts General Hospital), Chicago, 
IL (Rush Presbyterian-St. Luke's Medical Center), Oakland, CA (University of California Davis 
and Kaiser Permanente), Los Angeles, CA (University of California at Los Angeles), Newark, 
NJ (Mount Sinai Medical Center), and Pittsburgh, PA (University of Pittsburgh), with a central 
reproductive hormone laboratory, and a coordinating center located at the University of 
Pittsburgh Graduate School of Public Health (Pittsburgh, PA).  
SWAN surveyed over 16,000 women and enrolled 3302 women in the study who were 
aged 42 to 52 at the study entry (1996-97); all had an intact uterus and at least one ovary and had 
had one or more menstrual periods during the previous 3 months.
5
 They were not pregnant, 
breast-feeding, or taking reproductive hormones.
5
 Among the women enrolled, 1550 were 
Caucasian, 935 African American, 286 Hispanic, 250 Chinese and 281 Japanese. They were 
followed annually and all follow-up visits were scheduled based on the individual’s baseline 
 3 
index date (the day on which the first appointment for the baseline visit occurred). At each 
SWAN visit, the participants were evaluated for a wide spectrum of physiological, physical, 
behavioral and psychological measures. Details of the study design and recruitment process have 
been published previously.
7
 
1.2 STUDY BACKGROUND 
1.2.1 Bone Metabolism and Menopause 
In our body, bones are constantly remodeling. Approximately every ten years our skeleton is 
being completely renewed.
8
 During the bone turnover cycles, bone-resorbing osteoclasts and 
bone-forming osteoblasts are coupled and controlled by a variety of hormones and cytokines, as 
well as by mechanical loading.
9,10
 An increased activity of osteoclasts or decreased activity of 
osteoblasts leads to a decrease in bone mass or osteoporosis.  
Osteoporosis is a disease characterized by low bone mass and deterioration of bone 
structure, causing bone fragility and increased risk of fracture. According to the World Health 
Organization (WHO), osteoporosis is defined as having a BMD value less than 2.5 standard 
deviations from the young-adult normal value (T-score < 2.5).
11
 Millions of people worldwide 
suffer from osteoporosis, causing a big burden on the health system.
8
 Currently osteoporosis is 
an epidemic in the United States with approximately 9.1 million women and 2.8 million men 
afflicted with the disease in 2010.
12
  
Almost eighty percent of people who suffer from osteoporosis are women, with women 
over the age of 50 having the greatest risk of developing the disease.
12
 Since the average age of a 
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woman having her final menstrual period (FMP) is around 50, postmenopausal women have a 
high risk of developing osteoporosis. However, SWAN investigators found that BMD loss even 
began before the FMP. Greendale et al
13
 found that femoral neck BMD loss in White women 
started approximately 1 year before the FMP (year -1) and sharply declined about 1.76% 
annually until approximately 2 years after the FMP(year +2), thereafter, the BMD loss rate 
decelerated to 1.15% per year and did not cease. Similarly, the steep decline of femoral neck 
BMD occur in African American, Chinese and Japanese women as well, with a loss rate of 
1.42%, 2.17% and 2.13% respectively from year -1 to +2, and a loss rate of 1.09%, 1.01% and 
1.24% respectively after year +2. The cumulative 10 years lumbar spine BMD loss was 10.6% in 
White women and 7.38% was lost during the transmenopause.
2
 Similarly, cumulative 10 year 
femoral neck loss was 9.1% in White women and 5.8% was lost during the transmenopause.  
The accelerated BMD loss during transmenopause has clinical implications, most 
seriously bone fracture, which can lead to patient disability or even death. Various treatments are 
currently available to reduce the impact of bone fragility, but there is a lack of comprehensive 
treatment for the whole musculoskeletal system that leads to osteoporotic fracture.
14
 New 
treatments or prevention methods are needed, especially for women across the menopause. The 
SWAN study provides the investigators a means to explore secondary prevention strategies for 
menopausal women once bone loss has started or bone fractures have occurred. 
1.2.2 Blood Pressure and Menopause 
Since the 1980s, a number of studies in both humans and animal models of hypertension have 
suggested an association between hypertension and osteoporosis.
15-18
  Hypertension is one of the 
major risk factors for cardiovascular disease and also one component of the metabolic syndrome, 
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of which the incidence increases substantially during perimenopause and early menopause.
19
 
Martins et al, using data from NHANES III, conducted a cross-sectional study showing that 
gender or sex hormones have a prominent role in blood pressure regulation.
20
  Cross-sectional 
studies also show that postmenopausal women are at a higher risk of hypertension compared to 
age-matched men
20
 or their premenopausal counterparts
19
. Several cross-sectional studies 
concluded that either elevated blood pressure or incidence of hypertension is related to 
menopause independently of age by comparing two groups of women either in premenopausal 
status or in postmenopausal status. However, several limitations of these studies are noted 
including: not controlling for BMI and ethnicity in Weiss et al’ study21 and self-reported 
menopausal status not being verified retrospectively in Staessen et al’s research22.  
Furthermore, longitudinal and cross-sectional studies have produced mixed results on the 
relationship between hypertension and osteoporosis. Janssen et al
23
 investigated the metabolic 
syndromes occurred in the nature history of the menopausal transition among 949 participants, 
with 9 years’ follow-up in SWAN. They found that systolic blood pressure increased with aging 
but not significantly (p=0.07) and there was no effect of menopause on blood pressure. The study 
of health in Pomerania
24
 which was conducted on Mediterranean population, also failed to detect 
the significant change of blood pressure during the passage from premenopause to 
postmenopause independently of age with up to 6 years’ follow-up, but the conclusion may not 
be applicable to other ethnic groups or populations with different geographical or cultural 
conditions. The finding in Pizarra study
24
 was that the women who went from premenopause to 
postmenopause experienced no significant changes in blood pressure as compared with the 
women who did not yet have menopause. However, the sample size was insufficient to detect 
small effect sizes of interest. 
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Despite contradictory opinions on the effect of menopause on blood pressure, several 
mechanisms may explain the development of hypertension in postmenopausal women. These 
mechanisms involve cardiovascular risk factors, including weight and lipid levels; endothelial 
dysfunction, oxidative stress, inflammatory mediators and activation of the renin angiotensin and 
sympathetic systems.
19
 It remains uncertain whether these physiological changes are caused by 
the menopausal transition itself or by aging.  
Moreover, an age-related decrease in blood pressure control rates were more pronounced 
in women than in men, as shown by the Framinghan Heart Study.
25
 It is still unknown whether 
the decline in blood pressure control in women is due to sexual hormone related treatment 
resistance or due to non-optimal pharmacologic management in the clinical setting. Thus, the 
SWAN study provides the investigators with longitudinal observational data from the clinical 
setting, to answer further research questions regarding the effect of drug choices, independent of 
biological changes occurring during menopause. 
1.2.3 Factors associated with Bone Mineral Density 
Factors that are associated with bone mineral density include demographic, socioeconomic, 
genetic, hormonal, and nutritional factors, as well as body weight, and lifestyle choices such as 
diet (Calcium/Vitamin D supplement, alcohol consumption), smoking and exercise. Lack of 
exercise, low body mass index (BMI), absence of menses, family history of osteoporosis, alcohol 
abuse, and smoking are all the risk factors that lead to low BMD. Low BMI
26
 or low body weight 
affects premenopausal BMD and perimenopausal bone loss, shown by previously published 
SWAN data.
2
 Calcium and Vitamin D supplements show a protective effect on BMD. 
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The hypothesis of estrogen deficiency causing postmenopausal osteoporosis was first 
published in 1941 by Albright et al
19
, and this mechanism has been strongly supported by studies 
showing that estrogen administration prevented bone loss induced by oophorectomy in 
perimenopausal women.
27,28
 Although the mechanisms by which estrogen regulates bone 
turnover are not well understood, studies in animals suggest that estrogen acts by altering the 
activities of factors that regulate osteoblast and osteoclast precursors.
29,30
 Estrogen therapy is an 
effective option that increases bone mass; however, it produces a decrease in both bone 
formation and resorption associated with decreased remodeling. Moreover, because large 
randomized trials of hormone replacement therapy have called into question the long assumed 
protective effect of estrogen in heart disease risk, long term use of estrogen for increasing or 
maintaining BMD is not recommended.
31
  
Comorbidities or medications taken for other indications can profoundly affect BMD.
10
 
Effects that directly or indirectly affect bone metabolism may be beneficial or harmful. Cancer 
treatment-induced bone loss is generally more rapid and severe than bone loss associated with 
menopause in women.
32
 Other diseases, such as diabetes, arthritis or osteoarthritis, 
hyperthyroidism, and psychiatric comorbidities have demonstrable decreases in BMD.
33
  
The advances in the osteoporosis therapeutic field have been very significant over the last 
two decades. Other pharmacotherapies available for the management of the patients with low 
BMD are classified into two groups: antiresorptive and anabolic agents. The antiresorptive or 
anticatabolic agents, such as bisphosphonates, selective estrogen receptor modulators, hormone 
therapy, suppress or attenuate the activity of the bone-resorbing cells, the osteoclasts, hence 
stopping bone loss and increasing bone strength. Anabolic agents, such as parathyroid hormone, 
induce bone formation, reversing in part the deterioration induced by the osteoporosis 
 8 
progression. Although there are various treatments available for postmenopausal osteoporosis
10
, 
it is still important to develop preventive measures. 
Moreover, there are concerns regarding the side effects of the high dose or prolonged 
medications therapy. Following a thorough review of available safety data, the FDA has 
determined an osteoporosis and fracture warning on the over-the-counter proton pump inhibitor 
medication which has been used long-term to manage Gastroesophageal Reflux Disease.
34
 It is 
important to observe any drug effects over time, especially for drugs that need to be taken 
regularly, such as antihypertensive agents, especially when there is a lack of randomized 
controlled trials. 
1.2.4 Antihypertensive Medication Use and Bone Mineral Density  
If not treated effectively, hypertension can lead to an increased risk of heart attack, stroke and 
renal failure. The earliest pharmacological remedies to treat hypertension included nitrites, 
thiocyanates, dehydrogenated alkaloids of ergot, pyrogens, and veratrum viride.
35
 The most 
important breakthrough in the history of the drug treatment of hypertension came with the 
discovery of the orally effective diuretic, chlorothiazide in the late 1960s.
35
 
Antihypertensive medication use among US adults with hypertension has significantly 
increased over the past 10 years.
36
 The treatment of hypertension is based on the prescription of 
four major classes of antihypertensive drugs. According to the National Health and Nutrition 
Examination Survey from 2001 to 2010, the use of thiazide diuretics, β-blockers, angiotensin-
converting enzyme inhibitors, and angiotensin receptor blockers increased by 23%, 57%, 55%, 
and 26%, respectively.
36
 Despite the wide range of drugs available to lower blood pressure, there 
has not been a novel antihypertensive mechanism entering the market in more than a decade, 
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resulting in very few new drug therapies for hypertension.
37
 Therefore, it is crucial for physicians 
to optimize their antihypertensive therapies with the drugs available on the market.  
It has been confirmed in several studies that thiazide diuretics have a positive effect on 
BMD. To the author’s knowledge, there are three randomized controlled trials conducted to 
prove the protective effect. One randomized, double-masked, placebo-controlled trial examined 
the effect of chlorthalidone compared with placebo on three appendicular sites (calcaneus, distal 
radius and proximal radius) in 113 postmenopausal women in 1995, with an average of 2.6 years 
follow-up time
38
, and another randomized, double-blind, placebo-controlled trial was conducted 
using hydrochlorothiazide compared with using placebo in 320 healthy normotensive adults 
whose ages ranged from 60 to 79 and were followed for 3 years.
39
 The latter study shows that 
percentage increase of posterior-anterior spine BMD after treatment of low-dose 
hydrochlorothiazide (25mg per day) for 6 month was significantly greater (p =0.005) than the 
percentage increase in placebo group. However, only modest effects (0.82%; p = 0.12) were 
observed over 3 years. The study also concludes that the treatment effect on women is greater 
than men. Another clinical trial
40
 was performed for 2 years (and then a 2-year extension) on 185 
healthy postmenopausal women to examine hydrochlorothiazide’s effect (verse placebo) on 
BMD change over time. They found significant between-groups (hydrochlorothiazide and 
placebo) differences over the course of 4 years regarding the change in bone density of the total 
body (0.9%, p< 0.001), legs (1.0%, p = 0.002), mid-forearm (1.1%, p = 0.03), and ultradistal 
forearm (1.4%, p= 0.04), whereas, the BMD changes measured cumulatively for 4 years were at 
the lumbar spine (0.9%, p= 0.76) and femoral neck (0.4%, p = 0.53) did not differ between 
groups.  
 10 
Cross-sectional and longitudinal studies performed in humans have also demonstrated a 
slower rate of bone loss with thiazide diuretics therapy. Cauley et al
38
, using a cross-sectional 
study, came to a conclusion that women at least 65 years old and using thiazide diuretics for 
more than 10 years had significantly higher bone mass (calcaneus, distal radius and proximal 
radius distal radius) than women who had never used thiazide diuretics.
 
Wasnich et al
37 
concluded that rates of bone loss at all three sites (calcaneus, distal radius and proximal radius) 
were significantly reduced among men who took thiazide diuretics for an average of 11.9 years 
when compared with men who took antihypertensive durgs other than thiazide. Sower et al
41
 
conducted a prospective study and suggested that current users of the thiazide class of 
medications had less 5-year cumulative radial bone loss (5.0% vs 7.4%, p = 0.0035) than women 
without current thiazide use. In conclusion, the small scale, short term randomized controlled 
trials cannot provide conclusive proof regarding thiazide’ protective effect on BMD loss and the 
outcomes of the observational studies are rarely measured for lumbar spine, total hip and femoral 
neck.  Thus, observational studies provide important complementary evidence. 
For other antihypertensive drugs, there have been conflicting results. Of note, to the 
author’s knowledge, there have been no randomized controlled trials conducted in regard to 
angiotensin-converting enzyme inhibitors (ACE) or beta blocker with BMD values as the 
outcomes and there are fewer observational data, as well, for ACE or beta blocker than for 
thiazide diuretics. A cross-sectional study
42
 conducted in Chinese women whose age range from 
65 to 92, shows that ACE use compared to nonuse was associated with higher femoral neck 
BMD (0.015 g/cm2, p = 0.035) in women, but not associated with total hip or lumbar spine. 
Based on a 1-year prospective cohort study of 50 postmenopause women with hypertension 
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using fosinopril, García-Testal et al
43
 reported the loss of BMDs in lumbar spine and femoral 
neck was not significanly prevented.  
Likewise, the effect of beta blocker on human bones has been considered in only a few 
studies and the data are not consistent. Shuman et al
44
 used data from Dubbo Osteoporosis 
Epidemiology Study, which included 2203 women with a mean age of 68.7.  In women, beta 
blocker users had higher femoral neck BMD (p < 0.01) and higher lumbar spine BMD (p < 0.01) 
than those not on beta blocker in cross-sectional analyses. Pasco et al
45
 found that beta blocker 
use compared to nonuse was associated with a higher BMD at the total hip (2.5%, p = 0.03) and 
ultradistal forearm (3.6%, p = 0.04) in a population based, case-control study that used data for 
women, older than 50 years, and enrolled in the Geelong Osteoporosis Study. However, other 
studies have found beta blocker use and BMD loss to be unrelated. Rejnmark et al
46
 failed to find 
any significant difference in BMD at the lumbar spine and femoral neck between beta blocker 
treated and untreated women using a cross-sectional design with data from Danish Osteoporosis 
Prevention Study. Reid et al
47
  cannot identify any effect of beta blocker use on loss of hip or os 
calcis BMD over a mean follow-up of 4 years.  
It is possible that other groups of antihypertensive drugs, such as loop diuretics, 
spironolactone, calcium channel blockers and nitrates have an effect on BMD loss, but this paper 
only investigated the effects of ACE, beta blocker and thiazide diuretics. Other groups of 
antihypertensive drugs were neither reviewed, nor included in the following analyses due to the 
small number of people taking them. The following table (Table 1) summarizes the mechanism 
of ACE, beta blocker and thiazide for hypertension treatment, as well as potential effects on bone 
health.  
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Table 1: Summary of Mechanism of Antihypertensive Drugs and Bone Health 
 Mechanism to treat hypertension Potential Mechanism affecting bone health 
ACE The renin-angiotensin-aldosterone 
system (RAAS) plays a central 
role in the control of blood 
pressure and has been an important 
target of antihypertensive drug. 
ACE inhibitors affects RAAS 
axis.
48
 
Osteoblasts and osteoclasts express 
angiotensin-II type 1 receptor in cell cultures. 
Angiotensin-II induces the expression of 
receptor activator of NF-kappa B ligand 
(RANKL) in osteoblasts, leading to the 
activation of osteoclasts.
49
 In animal studies, 
both ACE inhibitors and ARBs have been 
shown to preserve BMD.
50
 
Beta 
Blockers 
Beta-adrenergic receptors are the 
sympathetic components of the 
autonomic nervous system. Beta 
blockers inhibit beta-adrenergic 
receptors, thus used in the 
treatment of hypertension.
51
 
In animal models, substantial evidence shows 
that sympathetic nerve fibers in bone tissue and 
functional adrenergic receptors in osteoblasts 
and osteoclasts.
52
 Another study shows that 
fenoterol, a beta-2 agonist, nearly doubled 
RANKL mRNA in human osteoclasts.
53
 
Thiazide Thiazide inhibits Na
+
/ Cl
-
 co-
transporters (NCCs) by decreasing 
sodium reabsorption, which leads 
to decreased extracellular fluid and 
plasma volume. The volume loss 
results in decreased blood 
pressure.
54
 
Thiazide inhibits the NCCs and the NCCs are 
also expressed in human osteoblast and 
osteoblast-like cells.
55
 If osteoblast cells were 
blocked by thiazide, it will enhance bone 
calcium uptake, consequently has a positive 
effect on BMD. 
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2.0  METHODS 
2.1 STUDY DESIGN 
To determine whether antihypertensive medication (ACE, beta blocker and thiazide) use was 
associated with lower bone loss rates, this study adopted three key design features: new-user 
design, frequency matching and propensity score matching.  
The new-user design
56
 identifies users who start a course of treatment with the 
medication of interest. Unlike using current medication users for the comparative group, the 
new-user design mainly identifies short-term users of the medication, which optimizes the ability 
to control for disease risk factors that may be altered by long-term medication use. In observance 
of the new-user design, exclusion criteria were defined as follows: any use of antihypertensive 
medications at the first SWAN visit, any use of antihypertensive drugs other than the category of 
interest (ACE, beta blocker and thiazide) before or at the baseline visit, and any combination use 
of antihypertensive drugs across categories at the visit of drug initiation. In this analysis, the 
study baseline visit for users was defined as the visit prior to the one where medication use was 
initiated, as long as the baseline visit was no more than 2 years before drug initiation. People 
without a defined baseline (no prior visits within 2 years of drug initiation) were excluded from 
the study. Any visit before the defined baseline was also excluded. 
 14 
The nonusers were defined as the participants who did not use any antihypertensive drugs 
throughout the SWAN study. Frequency matching was used to establish a comparable baseline 
for nonusers against the defined baseline for the antihypertensive drug users, with the aim of 
balancing the baseline characteristics, especially for menopause status. Frequency matching was 
designed by randomly assigning each nonuser a visit number (considered as baseline visit 
number) and the distribution of the randomly assigned visit numbers was patterned after the 
distribution of baseline visits for the users. The random number designating a SWAN visit was 
generated using SAS function (ranuni). Visits, if any, before the assigned baseline for the 
nonusers were excluded from this secondary analysis. The method was used in previous 
publication.
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Although frequency matching was used to balance the menopause status at baseline for 
each group, other characteristics at the baseline were still not balanced between the users and 
nonusers. When there are apparent baseline differences between groups, the possibility of bias 
arises: the outcome differences may not be due to the effect of the treatment per se, but rather on 
characteristics that initially determined whether or not a participant received a given treatment. 
Propensity score matching was used to eliminate biases and to improve balance of the measured 
baseline factors at the design phase of the observational study. Propensity scores were generated 
using the baseline characteristics, which were selected by stepwise regression, to estimate the 
probability of women being treated with antihypertensive medication versus not. The nonusers 
were matched to the users based on the propensity score. 
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2.2 STUDY POPULATION 
The study population was identified from 2,365 women enrolled in the SWAN bone substudy. 
The SWAN bone substudy is being carried out in five of the seven clinical sites (see Chapter 
1.1), located in Boston, Pittsburgh, the Detroit area, Oakland, and Los Angeles areas, who were 
self-defined as Caucasian, African American, Chinese, or Japanese (approximately half the 
women in each locale were self-defined Caucasians).
2
  
Participants who have a baseline BMD measurement and at least one additional 
measurement were eligible for this analysis. Nonusers and new users that are exclusive to one 
category of antihypertensive medication were identified as shown in Figure 1. The study 
included all women who met these criteria, but did not include women who used 
antihypertensive other than ACE, beta blocker or thiazide. 
Written informed consent was obtained from all participants, and each site’s protocol was 
conducted with approval from an institutional review board. The secondary data analysis 
presented in this paper has been approved by the SWAN Publication and Presentation (P&P) 
administrator and the P&P Chair. 
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                                                                Note: AHT--antihypertensive
Figure 1: Flowchart of the Study Cohort of Antihypertensive Drug Use and BMD Loss Analysis 
Figure 1: Flowchart of the Study Cohort of Antihypertensive Drug Use and BMD Loss Analysis 
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2.3 STUDY EXPOSURE 
The primary exposure of interest was antihypertensive medication use which was categorized as 
ACE, beta blocker or thiazide; antihypertensive drug users were compared to nonusers who had 
never used any types of antihypertensive medications. Censoring occurred when any visit 
switched the use of drug to a different category or any visit started combination therapy (added 
antihypertensive drug(s) from a different category).  
Medication data were coded using the Iowa Drug Information System (IDIS)
58
 and 
collected annually from both the interview portion and the specimen collection form. Medication 
information collected included identifiable prescription medication, over the counter medication 
that had been determined to be important by the pharmacoepidemiologist assisting SWAN or a 
Coordinating Center data analyst, and medications that are currently classified as over the 
counter medication that were classified as prescription medication at the start of SWAN. Dosage 
information was not available.  
2.4 STUDY OUTCOMES 
Outcomes of interest in this study were BMD loss of lumbar spine, femoral neck, and total hip, 
which were normalized to the defined baseline. To define the BMD loss, two types of loss rate, 
annual rate of change (measured BMD value at visit X/ measured BMD value at defined 
baseline) and loss rate change from the referent group (need to be added to the annual rate of 
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change of the referent group to get the absolute value), were used in this secondary analyses. 
Women in the SWAN Bone Study have annual measurements of lumbar spine, total hip and 
femoral neck aBMD by Hologic dual-energy X-ray absorptiometry (DXA).
2
 All SWAN 
measurements were made with QDR software. The scan machine model used at UCDavis and 
Pittsburgh is QDR 2000 prior to visit 8 and QDR 4500 was used from visit 8 forward; at the 
other 3 sites, QDR 4500 was used throughout all visits. To ensure comparable measurements 
between sites, Synarc machine drift correction factors specified to each site and scan date were 
applied on both lumbar spine and total hip BMDs. Moreover, the cross-calibration analyses 
between the QDR 2000 machine and QDR4500 machine were performed at the CC using 40 
people at each site. Only certified DXA operators can analyze scans for the SWAN study. 
Densitometer’s instruction manuals were provided to each site uniformly informing the scan 
specifications, positioning of the subject and defining the regions of interest. The quality control 
program for DXA measurements in SWAN has been published.
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A local Hologic anthropomorphic spine phantom was measured daily on each 
densitometer and a circulating Hologic anthropomorphic spine phantom was measured 
periodically on all densitometers. If retroactive analyses of these phantom measurements reveal 
significant longitudinal and/or cross-sectional deviation in the calibration of any densitometer, 
participant measurements from that densitometer during that interval are retroactively adjusted 
by the SWAN quality control center to eliminate this effect. These measures include low energy 
X rays of the lumbar spine, total hip, and whole body, which will provide an indication of bone 
strength, and predisposition to sustain fractures. 
For the spine region, the scan includes the vertebrae and sometimes there are collapsed 
vertebrae, vertebrae with focal sclerosis, or a metal overlying the spine. So in the calculation of 
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the total BMD, vertebrae situations listed above are excluded from statistical analysis and spine 
BMD value is recalculated as sum (Bone Mineral Content) divided by the sum (Area) based on 
non-excluded vertebras if more than one region is useable. On the other hand, if a woman is 
determined to have only one usable region at any SWAN visit, the spine scan is excluded at that 
visit and subsequent visits. Unlike the spine scans, the hip scan or femoral neck scan variables 
are not recalculated based on useable regions and the values are set to be missing if the regions 
are not useable. 
The BMD measurements selected in the analysis are among measurements from baseline 
through the SWAN follow-up visit 10 and visit 12. The visit 11 was not included in any of the 
analysis, because it is a non-funded visit, and quality of data collected cannot be guaranteed.  
2.5 OTHER PARAMETERS 
Several variables are considered as potential confounders and included in analyses. In SWAN, 
demographic variables (age, race, site, and education), annual income, marital status, life style 
factors (smoking history and alcohol consumption), self-assessed health status, social support, 
center for epidemiologic studies depression scale (CES-D), physical activity, and medication use 
(prescription hormone therapy (HT), bisphosphonates, proton pump inhibitors, 
thiazolidinediones, selective serotonin reuptake inhibitors, statins, beta-blockers, oral steroids, 
inhaled steroids, anti-convulstants, thiazide diuretics) were determined by either an interview-
administered or a self-administered questionnaire. Comorbid conditions (rheumatoid arthritis, 
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chronic obstructive pulmonary, and diabetes) were self-reported or determined from metabolic 
syndrome, or medication use. 
SWAN participants underwent physical measurements annually of weight and height. 
BMI was calculated using weight in kilograms divided by the square of height in meters. 
Physical activity was assessed using an adaptation of the Baecke questionnaire.
60
 It is a self-
reported instrument assessing sports, household, and daily routine, on the basis of the average 
responses to questions about various activities with scores ranging from 1(lowest) to 5(highest). 
A total physical activity score was calculated as the sum of the individual scores.  
Final menstrual period (FMP) was defined as the initial day of the last menstrual period 
preceding 12 consecutive months of amenorrhea, identified retrospectively. The women in whom 
we have not been able to observe a natural transition either used hormone therapy or had a 
hysterectomy. Menopause status was determined using self-reported bleeding patterns and 
categorized as pre-menopausal (if they had monthly bleeding during each of the last 3 months 
and noted no change in their prior individual menstrual pattern) or early perimenopausal (if they 
had menstrual bleeding in one, two, or three of the last 3 months and also noted a change in 
bleeding pattern from their prior menstrual pattern), or late menopausal (no menstrual bleeding 
for at least 3 months but no more than 12 months), and post-menopausal period (no menstrual 
bleeding for at least 12 months). Women reporting hysterectomy or oophorectomy were 
classified as surgically menopausal. Menopause transition stage was updated at each study visit. 
However, menopause status included in the analysis was redefined using FMP date, because a 
study using SWAN data found poor agreement between annual interview and menstrual calendar 
data for early menopausal transition.
61
 Therefore, for women who had a FMP date, pre-/ peri-
menopausal status was defined as one year before the FMP, late menopausal status was defined 
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as from one year before the FMP to 2 years after menopause, and postmenopausal status was 
classified as 2 years after menopause. On the other hand, for women whose FMP date was not 
yet confirmed, the self-report menopause status was used with the pre- and peri-menopause 
status collapsed into one group. 
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3.0  DATA ANALYSES 
3.1 LINEAR MIXED-EFFECT MODELING 
Descriptive statistics of the baseline demographic variables, annual income, education, marital 
status, BMI, smoking history and alcohol consumption, self-assessed health status, social 
support, physical activity, medication use, self-reported comorbid conditions were compared 
across medication groups. Continuous variables were analyzed using ANOVA and Kruskal-
Wallis tests, whereas categorical variables were analyzed using χ². Variables were transformed 
when necessary. 
The rate of loss in femoral neck, total hip and lumbar spine BMD were normalized to the 
baseline BMD and an annual percentage change was obtained. The normalized bone mineral 
density measurements were used as the response variables. This approach provided clinically 
interpretable results and allowed comparison to other studies. 
Linear mixed-effect regression modeling strategy was used, with random intercepts and 
slopes for each menopause stage. Because the rate of BMD loss varies greatly by menopause 
stage as discussed in Chapter 1.2.1, the fundamental modeling strategy was piecewise-defined, 
which accounted for the natural heterogeneity of BMD slopes in different menopause stages (see 
Appendix B). Because the interaction between drug effect and menopause stages was not 
statistically significant, the models were built under the assumption that the drug effect and 
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menopause stages act independently on BMD loss, in other words, their contributions are 
additive. Effect modification of the relationship between medication group and time and between 
menopause statuses on BMD loss (over time on the drug) was examined by the cross product 
term in the model. The coefficients estimated in the base model are intercepts for medications, 
pre-/peri-, late- and post- menopause status and slopes by medication group and slope by 
menopause status. Repeated measures were accounted by the correlation structure within 
subjects of random effect variance-covariance matrix (G matrix). For intercept and time 
variables (see Appendix B), the covariance between observations (G matrix) on the same subject 
were AR (1) with the assumption that correlation between repeated measures of BMD decreased 
toward zero with increasing time. For intercepts of late- and post-menopausal stages, the pattern 
of covariance between observations were not specified, which means that unstructured (UN) G 
matrix was used in the RANDOM statement. The same G matrix was also used for the slopes of 
all three menopausal stages. Default structure of error variance-covariance matrix (R) was used, 
which assumed that the errors for each subject were independently and identically distributed.  
Restricted Estimation Maximum Likelihood (REML) was used by the procedure PROC 
MIXED from the SAS System Software (Version 9.3). The Satterthwaite approximation
62
 for 
computing the denominator degrees of freedom for the tests of fixed effects was specified 
(ddfm=kr) in the procedure. It was used to adjust the estimated standard errors for fixed effects 
because the data were highly unbalanced. Akaike’s information criterion (AIC) and Schwarz’s 
Bayesian criterion (SBC) were used to select different covariance structures and to compare 
goodness of fit between models with the same fixed effects. Models with AIC or SBC values 
closest to zero were selected.  
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The covariates included in the adjusted model were selected using the likelihood ratio test 
(LRT), with statement (method=ml) specified in the PROC MIXED procedure. The models with 
forced in variables were considered as nested models, and the models that added other variables 
were considered as reference models. The LRT calculates the changes in deviance (-2LL) 
between the nested and reference models and statistically tests the change using a χ 2 distribution, 
with degrees of freedom equal to the change in number of parameters from the nested model to 
the referent model. The LRT was used to assess the model fit and test hypotheses about fixed-
effect parameters among the variables that potential confound the relation. The selection process 
was based on comparing the values of likelihood functions for two models, with the same 
variance-covariance parameters. Variables that were forced in the models were pre-decided, 
including total number of comorbidities, physical activities, and other medication use (hormone 
therapy, diabetes related medication use, bisphosphonates and antidepressants). All analyses 
were performed in SAS (version 9.3). 
3.2 PROPENSITY SCORE ANALYSES 
The propensity score was defined as the probability of receiving the antihypertensive treatment 
(ACE, beta blocker or thiazide). Propensity score matching was used to improve the balance of 
the distributions of observed baseline factors between the treatment group and control group. 
Therefore, propensity score matching was used to maximize exchangeability across groups and 
estimate the average treatment effect. In this analysis, three sets of nonuser comparative groups 
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were generated separately to match ACE, beta blocker, and thiazide groups and three different 
models (one for each drug) were built for the same outcome. 
Propensity scores were estimated using binary logistic regression models with the 
treatment choices as the outcomes. The models were built using stepwise regression which 
selected baseline variables that are associated with the outcome. Figure 2 shows the density plot 
of predicted probability (p-hat) which was generated from the model and shows the comparison 
between the drug group and nonusers before optimal matching. Optimal matching SAS macros 
were used to match the nonusers who have the closet logit transformed p-hat to the drug groups. 
The largest possible absolute differences between the logit (p-hat) for drug group and a valid 
compatible matched nonuser group were set as 1. Propensity score matching created 1:1 matched 
pairs of ACE vs. nonusers, beta blocker vs. nonusers, and Thiazide vs. nonusers. Figure 3 shows 
the density plot of p-hat for drug group and optimal matched nonusers. The macros were 
developed by Mayo Clinic staff in SAS System Software (Version 9.3) (Copyright 2005 Mayo 
Foundations for Medical Education and Research). A similar modeling strategy was used for the 
propensity matched sets of women with regard to linear mixed effect regression of BMD as 
described in Chapter 3.1. 
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Figure 2: Propensity Score Distribution Comparison between Antihypertensive Users (ACE, beta blocker and Thiazide) and Nonuser before propensity score 
matching. 
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Figure 3: Propensity Score Distribution Comparison between Antihypertensive Users (ACE, beta blocker and Thiazide) and Nonuser after propensity score 
matching.
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4.0  RESULTS AND CONCLUSIONS 
4.1 BASELINE CHARACTERISTICS 
Of the 2,365 women enrolled in the SWAN bone substudy, 534 were excluded because they 
reported use of a antihypertensive drug at the initial SWAN visit and 58 were excluded for 
lacking eligible baseline (no prior visits within 2 years of drug initiation) or because of using 
antihypertensive drugs across categories at baseline. Among the 1,436 women who never used 
any antihypertensive medications, 151 were excluded for only having one visit in total, and 185 
women could not be matched to the users’ baseline visit distribution and were excluded from the 
analysis. In the end, 132 participants were excluded due to lack of a follow-up BMD. The final 
analytic cohort has 1305 women in total, among which there are 107 (8.2%) women who 
initiated beta blocker use during the follow-up period, 98 (7.5%) who initiated ACE use, 99 
(7.6%) who initiated thiazide use and also there are 1001 (76.7%) women who did not report any 
antihypertensive drug use at any visit included (Table 3). The top 3 prevalent drugs used within 
each category are displayed in Table 2, along with drug structure and time introduced into 
market. 
A total of 1305 participants were included in the analyses, with an average age of 51.5 
(±4.2) years. The average follow-up time of subjects included in the analysis is 7.5 (±3.6) years. 
The baseline characteristics of the participants included in the study are detailed in Table 3. The 
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antihypertensive class initiated varied significantly (p-value <0.05) by demographic variables, 
including sites, education, income; self-reported comorbidities (heart problems, hyperlipidemia, 
and arthritis); medication use (diabetes related medication and proton pump inhibitor); and 
lifestyle factors (alcohol/tobacco use), and other risk factors including BMI, menopause status, 
self-rated health status, physical activity, and CES-D. 
The nonuser group generally had a higher education level, higher income, lower BMI, 
less current or past tobacco use, higher alcohol consumption, higher physical activity and had a 
predominantly white population and relatively less black people compared to the all of the user 
groups. Almost 60% of the participants in the nonuser group self-classified as having excellent 
or very good health status, with less self-reported overactive or underactive thyroid conditions, 
hyperlipidemia, and arthritis; and in terms of medication use, nonuser had less use of diabetes 
related medications, antidepressants, and proton pump inhibitor. 
Populations who were using regimens involving ACE and thiazide were more similar to 
one another in terms of menopause status, CES-D score, and BMI. Both groups had a higher 
percent of postmenopausal women at the baseline, higher depression score, and more obese 
people than populations using regimens involving beta blocker or nonusers. The baseline BMD 
values at lumbar spine, total hip and femoral neck were imbalanced, but the baseline values were 
not adjusted in the models, because the outcomes used were BMD values which were normalized 
to the baseline. 
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Table 2: Top 3 Drugs Which Initiated within Each Antihypertensive Category (Time introduced into therapy and structure) 
 ACE Structure Beta Blocker Structure  Thiazide Structure 
Lisinopril 
 (Early 1990s) 
 
Atenolol 
 (1980s) 
 
Hydrochloro-
thiazide 
 (1970s) 
 
Enalapril 
 (1980s) 
 
Metoprolol 
 (1970s) 
 
Triamterene 
 (1964) 
 
Benazepril 
 (1991) 
 
Propranolol 
(1970s) 
 
Chlor-
thalidone 
 (1980s) 
 
*Note: Time introduced into therapy was listed under the drug names.
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Table 3: Baseline Characteristics of Subjects included in Study Cohort 
Characteristic 
ACE BB Thiazide Nonuser p-value 
(N=98) (N=107) (N=99) (N=1001)   
Demographics           
Age, mean, SD 52.1, 4.2 51.3, 4.3 52.0, 4.2 51.1, 4.2 0.0636 
Race/Ethnicity, %         p>=.50 
  Caucasian 54.1 48.6 37.4 57.1   
  Black 28.6 23.4 47.5 16   
  Chinese 8.2 14 12.1 12.7   
  Japanese 9.2 14 3 14.2   
Site, %           
  Michigan 30.6 23.4 21.2 14.1 0.004 
  MGH 21.4 14 32.3 19.3   
  UCDavis 12.2 19.6 19.2 23.9   
  UCLA 17.3 23.4 6.1 25.4   
  Pittsburgh 18.4 19.6 21.2 17.4   
Education, %         0.0016 
  High School or less 3.1 6.5 2.1 2.3   
  High School/some college 66.3 42.1 58.8 44.1   
  College degree 10.2 21.5 15.5 25.9   
  Post College 20.4 29.9 23.7 27.8   
Marital status, %         p>=.50 
  Single/Never married 15.3 17.8 15.2 12.8   
  Currently married 59.2 63.6 63.6 67.8   
  Separated/Widowed/Divorced 25.5 18.7 21.2 19.3   
Income, %         0.0008 
  <20K 9 12.9 7.5 5.9   
  20-<35K 13.5 13.9 16.1 9.6   
  35-<50K 23.6 13.9 16.1 15.6   
  50-<75K 18 16.8 25.8 24.3   
  >75K 36 42.6 34.4 44.6   
BMI at visit 0, mean, SD 31.2, 6.8 27.7, 6.6 30.5, 6.4 26.4, 5.9 <.0001 
BMI category, %         <.0001 
  Obese 52 29.5 53.5 22.7   
  Overweight 28.6 31.4 26.3 28.3   
  Normal 19.4 39 20.2 49   
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Table 3 (cont.) Baseline Characteristics of Subjects included in Study Cohort 
 
Characteristic 
ACE BB Thiazide Nonuser p-value 
(N=98) (N=107) (N=99) (N=1001)   
Self-reported Comorbidities           
  Heart problem, % 1 3.7 0 0.7 0.0909 
  Thyroid, % 14.6 15.9 11.1 10 0.0403 
  Cancer, % 2 0 1 0.9 p>=.50 
  Hyperlipidemia, % 28.6 19.6 21.2 13.8 <.0001 
  Arthritis or osteoarthritis, % 20.6 19.6 22.2 13 0.0037 
  Osteoporosis, % 4.1 2.8 2 3.4 p>=.50 
Other Medication Use           
  Ever Reported HT Use, % 25.5 29 35.4 24 0.2169 
  Diabetes Related Medication, % 24.5 2.8 2 1.7 <.0001 
  Bisphosphonates, % 1 1.9 2 2.7 0.2572 
  Hydantoins, % 2 4.7 0 1.3 0.1045 
  Antidepressants, % 17.3 14 14.1 11.6 0.076 
  H2 Antagonists, % 0 7.5 7.1 3.4 p>=.50 
  Proton Pump Inhibitors, % 7.1 4.7 7.1 2.9 0.0131 
  Supplement Calcium (mg), % 31.9 23.7 36.8 36.7 0.082 
  Supplement Vitamin D (IU), % 8.3 3.9 9.2 7.8 p>=.50 
Other Risk Factors of Interests           
Menopausal status, %         0.0863 
  Post menopause 28.6 15.8 26.8 18.7   
  Late menopause 37.4 41.1 29.3 38.5   
  Pre-/Peri-menopause 34.1 43.2 43.9 42.9   
Self-rated Health Category, %         <.0001 
  Fair or poor 12.4 17.5 11.2 10.5   
  Good 46.4 40.8 51 30.1   
  Excellent or very good 41.2 41.7 37.8 59.4   
Alcohol intake, %         0.0135 
  No (< once/month) 56.4 60.2 49.5 46.8   
  Moderate use(> once/month) 20.2 21.4 34.3 27.6   
  High use (>=2 times/week) 23.4 18.4 16.2 25.5   
Tobacco use, %         0.0008 
  Never 77.3 83 73.7 87.8   
  Past 5.2 6.6 8.1 3.5   
  Current 17.5 10.4 18.2 8.7   
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Table 3 (cont.) Baseline Characteristics of Subjects included in Study Cohort 
 
Characteristic 
ACE BB Thiazide Nonuser p-value 
(N=98) (N=107) (N=99) (N=1001)   
Physical Activity, mean, SD 7.3, 1.4 7.7, 1.5 7.6, 1.6 8.0, 1.5 <.0001 
Binary CES-D Score, % 28.4 16 22.2 16.1 0.0097 
CES-D Scale Score, mean, SD 11.6, 11.3 8.8, 8.5 9.9, 10.2 8.5, 8.4 0.1225 
Social Support Scale Score, 
mean, SD 
12.5, 2.9 12.5, 3.0 12.9, 2.8 13.0, 3.0 0.093 
Ever fracture a bone, % 1 2.8 4 2.3 p>=.50 
Reported high blood pressure, 
% 
21.9 7.5 25.5 3.6 <.0001 
BMD, g/cm2 (SD)           
  Lumbar spine, mean, SD 1.08, 0.15 1.03, 0.13 1.06, 0.15 1.02, 0.15 0.0003 
  Total hip, mean, SD 0.98, 0.15 0.92, 0.14 0.97, 0.14 0.92, 0.14 <.0001 
  Femoral neck, mean, SD 0.83, 0.13 0.78, 0.12 0.85, 0.14 0.80, 0.13 0.0004 
Abbreviations: BB, Beta Blocker; BMI, body mass index (calculated as weight in kilograms divided by height in 
meters squared); HT, hormone therapy; Michigan, University of Michigan, Ann Arbor, Michigan; MGH, 
Massachusetts General Hospital, Boston, Massachusetts; UCDavis, University of California, California; UCLA, 
University of California, Los Angeles, California; Pittsburgh, University of Pittsburgh, Pittsburgh, Pennsylvania; 
CES-D, Center for Epidemiologic Studies Depression Scale. 
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4.2 BASELINE CHARACTERISTICS FOR PROPENSITY SCORE ANALYSES 
Propensity score matching was used with a 1:1 matching ratio and the comparison baseline table 
is shown in Table 4. The 69 ACE users, 88 beta blocker users and 76 diuretics users, were 
matched with an equal number of nonusers, respectively. Although there is a general pattern of 
balanced baseline characteristics in the matched sets and a great improvement relative to the 
unmatched comparisons, a few recurring differences stand out.  Use of H2 antagonists between 
ACE users and nonusers is imbalanced (p =0.0011) and there is no one in the ACE group who 
uses H2 antagonists, whereas 14.5% of nonusers reported the using it. The use of anticonvulsants 
is imbalanced between beta blocker users and nonusers (p =0.0437) with only 4.5% of ACE 
users and 0% nonusers. The mean of social support scale score for beta blocker users is 12.3 
(±3.1) and 13.4 (±2.7) for nonusers. There are significantly (p =0.0063) more current and past 
smokers in the thiazide users compared to the nonusers.
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Table 4: Baseline Characteristics of Subjects Initiated ACE, Beta Blocker, Thiazide and Propensity Score Matched Nonusers 
Characteristic 
ACE Nonuser 
p-
value 
BB Nonuser 
p-
value 
Thiazide Nonuser 
p-
value 
(N=69) (N=69)   (N=88) (N=88)   (N=76) (N=76)   
Demographics                   
Age, mean, SD 52.0, 4.1 52.0, 4.3 p>=.50 51.3, 4.4 51.9, 4.5 0.3645 52.0, 4.4 52.7, 4.3 0.2945 
Race/Ethnicity, %     p>=.50     0.3198     0.3713 
  Caucasian 56.5 59.4   51.1 58   35.5 47.4   
  Black 23.2 24.6   20.5 18.2   47.4 35.5   
  Chinese 10.1 7.2   14.8 14.8   13.2 13.2   
  Japanese 10.1 8.7   13.6 9.1   3.9 3.9   
Site, %     p>=.50     0.2173     p>=.50 
  Michigan 29 27.5   22.7 27.3   21.1 23.7   
  MGH 21.7 20.3   15.9 18.2   31.6 21.1   
  UCDavis 15.9 13   19.3 23.9   21.1 25   
  UCLA 17.4 17.4   25 18.2   6.6 9.2   
  Pittsburgh 15.9 21.7   17 12.5   19.7 21.1   
Education, %     p>=.50     p>=.50     p>=.50 
  High School or less 4.3 4.3   6.8 3.4   2.7 2.6   
  High School/some college 63.8 63.8   40.9 48.3   58.1 59.2   
  College degree 14.5 11.6   22.7 21.8   14.9 15.8   
  Post College 17.4 20.3   29.5 26.4   24.3 22.4   
Marital status, %     p>=.50     0.0847     p>=.50 
  Single/Never married 13 13   19.3 8   17.1 15.8   
  Currently married 60.9 58   63.6 71.6   64.5 63.2   
  Separated/Widowed/Divorced 26.1 29   17 20.5   18.4 21.1   
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Table 4(cont.): Baseline Characteristics of Subjects Initiated ACE, beta blocker, Thiazide and Propensity Score Matched Nonusers 
Characteristic ACE Nonuser 
p-
value 
BB Nonuser 
p-
value 
Thiazide Nonuser 
p-
value 
 
(N=69) (N=69)   (N=88) (N=88)   (N=76) (N=76)   
Income, %     0.0453     p>=.50     p>=.50 
  <20K 6.2 11.9   13.1 6.8   7.1 9.3   
  20-<35K 9.2 23.9   9.5 12.5   17.1 17.3   
  35-<50K 24.6 16.4   13.1 15.9   15.7 20   
  50-<75K 21.5 17.9   20.2 21.6   27.1 17.3   
  >75K 38.5 29.9   44 43.2   32.9 36   
BMI at visit 0, mean, SD 30.4, 6.2 30.7, 6.6 p>=.50 27.6, 6.4 28.8, 7.0 0.2736 29.9, 6.6 30.3, 6.3 p>=.50 
BMI category, %     p>=.50     0.4585     1 
  Obese 52.2 47.8   29.5 33   47.4 48.7   
  Overweight 27.5 29   33 35.2   30.3 27.6   
  Normal 20.3 23.2   37.5 31.8   22.4 23.7   
Self-reported Comorbidities                   
  Heart problem, % 0 1.4 0.3173 3.4 3.4 1 0 2.6 0.1559 
  Thyroid, % 11.6 14.5 p>=.50 13.6 12.5 p>=.50 10.5 12 p>=.50 
  Cancer, % 1.4 0 0.3173 0 3.4 0.0832 0 1.3 0.3173 
  Hyperlipidemia, % 24.6 27.5 p>=.50 21.6 19.3 p>=.50 17.1 26.3 0.1699 
  Arthritis or osteoarthritis, % 22.1 21.7 p>=.50 19.3 22.7 p>=.50 22.4 17.1 0.4165 
  Osteoporosis, % 4.3 2.9 p>=.50 3.4 6.9 0.3059 1.3 3.9 0.3125 
Other Medication Use                   
Ever Reported HT Use, % 23.2 23.2 1 21.6 20.5 p>=.50 25 22.4 p>=.50 
Diabetes Related Medication,% 20.3 14.5 0.3707 3.4 4.5 p>=.50 1.3 5.3 0.1739 
Bisphosphonates, % 1.4 1.4 1 2.3 3.4 p>=.50 2.6 2.6 1 
Hydantoins, % 1.4 1.4 1 4.5 0 0.0437 0 1.3 0.3173 
37 
 
Table 4(cont.): Baseline Characteristics of Subjects Initiated ACE, beta blocker, Thiazide and Propensity Score Matched Nonusers 
Characteristic ACE Nonuser 
p-
value 
BB Nonuser 
p-
value 
Thiazide Nonuser 
p-
value 
 
(N=69) (N=69)   (N=88) (N=88)   (N=76) (N=76)   
Other Medication Use (cont.)                   
  Antidepressants, % 15.9 13 p>=.50 17 18.2 p>=.50 7.9 7.9 1 
  H2 Antagonists, % 0 14.5 0.0011 9.1 9.1 1 6.6 3.9 0.469 
  Proton Pump Inhibitors, % 4.3 2.9 p>=.50 3.4 6.8 0.306 7.9 7.9 1 
  Supplement Calcium (mg), % 39.2 42.9 p>=.50 23.8 31.8 0.3126 35.6 37.3 p>=.50 
  Supplement Vitamin D(IU),% 11.8 14.3 p>=.50 4.8 12.1 0.1362 11.9 15.3 p>=.50 
Other Risk Factors of Interests  
Menopausal status, %           p>=.50     0.3098 
  Post menopause 26.1 24.6 p>=.50 15.9 20.5   27.6 26.3   
  Late menopause 39.1 39.1   39.8 37.5   27.6 43.4   
  Pre-/Peri-menopause 34.8 36.2   44.3 42   44.7 30.3   
Self-rated Health Category, %     p>=.50     p>=.50     p>=.50 
  Fair or poor 10.1 18.8   19 21.6   11.8 15.8   
  Good 47.8 27.5   38.1 25   48.7 39.5   
  Excellent or very good 42 53.6   42.9 53.4   39.5 44.7   
Alcohol intake, %     p>=.50     p>=.50     p>=.50 
  No (< once/month) 58 47.8   60.2 58   51.3 48.7   
  Moderate use(> once/month) 18.8 31.9   21.6 19.3   32.9 30.3   
  High use (>=2 times/week) 23.2 20.3   18.2 22.7   15.8 21.1   
Tobacco use, %     0.2072     0.0622     0.0063 
  Never 79.7 87   79.3 90.9   69.7 89.5   
  Past 4.3 4.3   8 2.3   7.9 1.3   
  Current 15.9 8.7   12.6 6.8   22.4 9.2   
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Table 4(cont.): Baseline Characteristics of Subjects Initiated ACE, beta blocker, Thiazide and Propensity Score Matched Nonusers 
Characteristic ACE Nonuser 
p-
value 
BB Nonuser 
p-
value 
Thiazide Nonuser 
p-
value 
 
(N=69) (N=69)   (N=88) (N=88)   (N=76) (N=76)   
Physical Activity, mean, SD 7.3, 1.4 7.4, 1.3 p>=.50 7.8, 1.6 7.9, 1.4 0.4488 7.5, 1.7 7.7, 1.5 p>=.50 
Binary CES-D Score, % 23.2 20.3 p>=.50 18.2 22.7 0.4561 21.1 17.1 p>=.50 
CES-D Scale Score, mean, SD 10.1, 10.5 10.3, 9.0 0.4843 9.2, 8.7 10.3, 8.8 0.3942 9.5, 9.5 9.2, 9.2 p>=.50 
Social Support Scale Score, 
mean, SD 
12.8, 2.8 12.3, 3.3 0.4844 12.3, 3.1 13.4, 2.7 0.0099 12.9, 2.9 12.6, 3.2 p>=.50 
Ever fracture a bone, % 1.4 4.3 0.312 3.4 2.3 p>=.50 5.3 3.9 p>=.50 
Reported high BP, % 19.1 14.5 0.4706 8 11.4 0.46 21.1 23.7 p>=.50 
BMD, g/cm2 (SD)                   
  Lumbar spine, mean, SD 1.07, 0.16 1.07, 0.17 p>=.50 1.02, 0.14 1.03, 0.17 1 1.05, 0.14 1.05, 0.17 p>=.50 
  Total hip, mean, SD 0.96, 0.14 0.99, 0.15 0.3078 0.92, 0.15 0.95, 0.16 0.2427 0.97, 0.14 0.98, 0.15 p>=.50 
  Femoral neck, mean, SD 0.81, 0.12 0.85, 0.16 0.1826 0.78, 0.12 0.84, 0.16 0.0203 0.84, 0.15 0.84, 0.16 p>=.50 
Estimated Probability 
a
, mean, 
SD 
.32, .23 .31, .22 p>=.50 .20, .14 .20, .15 p>=.50 .21, .17 .21, .16 p>=.50 
Abbreviations: BB, Beta Blocker BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); HT, hormone therapy; 
Michigan, University of Michigan, Ann Arbor, Michigan; MGH, Massachusetts General Hospital, Boston, Massachusetts; UCDavis, University of California, 
California; UCLA, University of California, Los Angeles, California; Pittsburgh, University of Pittsburgh, Pittsburgh, Pennsylvania; CES-D, Center for 
Epidemiologic Studies Depression Scale; BP, blood pressure.                                                                                                                                                                  
a
 Propensity Score (ACE vs. Nonuser) was estimated based on baseline variables including average SBP, average DBP, ethnicity, site, menopause status, BMI, 
CES-D, education, alcohol consumption, ever used antidepressants, ever used HT, ever used H2 antagonists, ever used diabetes related medication, ever used 
bisphosphonates, total number of comorbidities, self-reported health condition, hyperlipidemia, self-reported thyroid and physical activity. Propensity Score (BB 
vs. Nonuser) was estimated based on baseline variables including average SBP, ethnicity, menopause status, BMI, alcohol consumption, ever used 
antidepressants, ever used H2 antagonists, total number of comorbidities, and self-reported heart problem. Propensity Score (Thiazide vs. Nonuser) was 
estimated based on baseline variables including average DBP, age, site, menopause status, BMI, ever used antidepressants, ever used proton pump inhibitor, and 
self-reported health condition.
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4.3 MULTIVARIATE MIXED MODELS (FREQUENCY MATCHING) 
Table 5 and 6 show the unadjusted model for predicting lumbar spine, total hip and femoral neck 
BMD over time. Table 7 and 8 present the models adjusted for age, ethnicity, site, BMI, number 
of comorbidities, physical activity, and other medication use (hormone therapy, diabetes related 
medication, bisphosphonates and antidepressants). 
In the unadjusted model, the average rates of change among nonusers are shown in the 
Table 9 and the slope of lumbar spine BMD was -0.414% per year, -0.567% per year for total hip 
BMD and -0.676% per year for femoral neck BMD. Compared to the nonusers, thiazide users 
have a significantly lower annualized rate of BMD loss at lumbar spine (-0.215%, p =0.0005), 
total hip (-0.213%, p =0.02) and femoral neck (-0.310%, p <0.0001). ACE is not associated with 
lumbar spine (p =0.07), total hip (p =0.64) or femoral neck (p=0.91). Beta blocker use is not 
significantly associated with annualized loss of lumbar spine BMD (p =0.13) or total hip BMD 
(p =0.95), but beta blocker shows a nominal significance (p =0.05) on protecting femoral neck 
BMD loss but is not statistically significant after adjustment for multiple comparisons nor is it 
significant in the multivariable models (p =0.06) shown in Table 8.  
In the adjusted model, Caucasian women with average BMI of 27.64kg/m
2
 and average 
age of 53.77 years were treated as the reference sample. Age, BMI, and physical activity were 
used as time-varying variables and Pittsburgh was used as the reference level for site. Chinese 
and Japanese were grouped as the “Asian” category. The total number of self-reported 
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comorbidities was counted (maximum was 7) and other medication use was recoded depending 
on whether the drug was ever used at the visit of interest from self-reported medication data.  
After adjustment for the above variables, thiazide’s protective effect is consistent with the 
unadjusted models. Compared to nonusers, we estimate that the lumbar spine BMD loss 
decreased by 0.381% (p =0.0002) per year, total hip BMD loss decreased by 0.229% (p =0.0046) 
per year and femoral neck BMD loss decreased by 0.375% (p <.0001) per year. Neither ACE nor 
beta blocker had any effect on BMD on any of the sites. Although thiazide has a protective effect 
on BMD loss, the slope of the thiazide group still sharply declined in late menopause.  
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Table 5: Unadjusted Mixed Model for Lumbar Spine, Total Hip and Femoral Neck (Frequency Matching) 
  Lumbar Spine Total Hip Femoral Neck 
Variable Coefficient P-value Coefficient P-value Coefficient P-value 
Intercept 97.810% <.0001 98.710% <.0001 97.860% <.0001 
  Medication Category   0.0007   0.0002   <.0001 
    ACE (vs. Non) 0.393% 0.133 -0.032% 0.8808 0.009% 0.972 
    BB (vs. Non) 0.478% 0.0389 0.413% 0.0257 0.815% 0.0004 
    Thiazide (vs. Non) 0.873% 0.0004 0.782% <.0001 1.496% <.0001 
  Pre-/Peri-menopause 2.276% <.0001 1.776% <.0001 1.828% <.0001 
  Late menopause -1.248% <.0001 -0.919% <.0001 -0.714% <.0001 
  Post menopause -1.328% <.0001 -1.122% <.0001 -1.104% <.0001 
Slope 
  Time -0.567% <.0001 -0.414% <.0001 -0.676% <.0001 
  Time*Medication    0.0012   0.1075   0.0003 
    Time*BB (vs. Non) 0.150% 0.1309 -0.005% 0.9453 0.169% 0.0542 
    Time*ACE (vs. Non) 0.185% 0.0672 0.038% 0.6426 -0.010% 0.9102 
    Time*Thiazide (vs. Non) 0.352% 0.0005 0.201% 0.015 0.366% <.0001 
  Time*Pre/Peri menopause 0.564% <.0001 0.529% <.0001 0.556% <.0001 
  Time*Late menopause -0.602% <.0001 -0.343% <.0001 -0.278% <.0001 
  Time*Post menopause -0.171% 0.0034 -0.260% <.0001 -0.183% 0.0017 
Abbreviations: Non, Nonusers; BB, Beta Blocker; #, number; Time, Time been on the drug. 
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Table 6: Influence of Antihypertensive Medications on Annual BMD Slopes Summary for Lumbar Spine, Total Hip 
and Femoral Neck Bone Mineral Density (BMD) (Frequency Matching--Unadjusted Model) 
Annual BMD Slopes Summary for Lumbar Spine, Total Hip and Femoral Neck BMD 
  (95% Confidence interval) 
 Lumbar Spine Total Hip Femoral  Neck 
Referent a -0.567% ( -0.622% , -0.512% ) -0.414% ( -0.459% , -0.369% ) -0.676% ( -0.730% , -0.622% ) 
Change from referent group c 
ACE 0.185% ( 0.084% , 0.285% ) 0.038% ( -0.044% , 0.121% ) -0.010% ( -0.099% , 0.079% ) 
Beta Blocker 0.150% ( 0.051% , 0.250% ) -0.005% ( -0.085% , 0.075% ) 0.169% ( 0.082% , 0.257% ) 
Thiazide 0.352% ( 0.251% , 0.453% ) 0.201% ( 0.119% , 0.284% ) 0.366% ( 0.274% , 0.457% ) 
a 
Slope referent values are for Nonusers.                                                                                                                           
b
 Statistically significant associations are shown in bold italic typeface.                                                                         
c
 To get slopes for medications, number needs to be added to the nonuser slope referent values. 
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Table 7: Adjusted Mixed Model for Lumbar Spine, Total Hip and Femoral Neck (Frequency Matching) 
  Lumbar Spine Total Hip Femoral Neck 
Variable Coefficient P-value Coefficient P-value Coefficient P-value 
Intercept 97.530% <.0001 98.160% <.0001 98.210% <.0001 
  Medication Category   <.0001   <.0001   <.0001 
    ACE (vs. Non) 0.478% 0.0847 0.189% 0.4022 -0.263% 0.3457 
    BB(vs. Non) 0.617% 0.0084 0.399% 0.0319 0.777% 0.0008 
    Thiazide (vs. Non) 1.145% <.0001 0.955% <.0001 1.431% <.0001 
  Pre-/Peri-menopause 1.898% <.0001 1.550% <.0001 1.645% <.0001 
  Late menopause -0.955% <.0001 -0.400% 0.0132 -0.244% 0.232 
  Post menopause -0.886% <.0001 -0.500% 0.0032 -0.542% 0.0074 
Slope 
  Time  -0.481% <.0001 -0.320% <.0001 -0.599% <.0001 
  Time*Medication    0.0004   0.0384   0.0002 
    Time*BB (vs. Non) 0.162% 0.0986 -0.020% 0.8032 0.164% 0.0608 
    Time*ACE(vs. Non) 0.185% 0.0645 0.044% 0.5897 -0.017% 0.8503 
    Time*Thiazide(vs.Non) 0.381% 0.0002 0.229% 0.0046 0.375% <.0001 
  Time*Pre/Peri menopause 0.555% <.0001 0.512% <.0001 0.543% <.0001 
  Time*Late menopause -0.586% <.0001 -0.340% <.0001 -0.271% <.0001 
  Time*Post menopause -0.136% 0.0205 -0.220% <.0001 -0.160% 0.0058 
Demographics 
Age (center at 53.77) -0.155% <.0001 -0.160% <.0001 -0.139% <.0001 
Ethinicity    0.0003   <.0001   0.1236 
  Black (vs. Caucasion) -0.662% <.0001 -0.600% <.0001 -0.347% 0.0409 
  Asian (vs. Caucasion) 0.118% 0.4637 0.063% 0.6271 0.007% 0.9659 
SITE   0.0019   <.0001   <.0001 
  UCDavis(vs. Pittsburgh) 0.113% 0.5475 0.230% 0.1263 -0.612% 0.0016 
  UCLA (vs. Pittsburgh) 0.169% 0.3575 -0.700% <.0001 -0.872% <.0001 
  Michigan(vs. Pittsburgh) 0.577% 0.0017 -0.400% 0.0073 -1.184% <.0001 
  MGH (vs. Pittsburgh) 0.603% 0.0006 -0.160% 0.2458 -0.906% <.0001 
BMI (center at 27.64) 0.067% <.0001 0.052% <.0001 0.079% <.0001 
Total # of Comorbidities -0.102% 0.0521 0.026% 0.5348 0.025% 0.6436 
Physical Activity -0.012% 0.7125 0.034% 0.2066 -0.012% 0.7304 
Other Medication Use 
  Ever Reported HT Use 0.241% 0.1284 0.485% 0.0001 0.350% 0.0283 
  Diabetes Related Meds -0.492% 0.0734 -1.050% <.0001 -0.027% 0.9228 
  Bisphosphonates 2.006% <.0001 1.455% <.0001 1.543% <.0001 
  Antidepressants 0.259% 0.0553 0.249% 0.0213 0.373% 0.0076 
Abbreviations: Non, Nonusers; BB, Beta Blocker; #, number; Time, Time been on the drug. 
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Table 8: Influence of Antihypertensive Medications on Annual BMD Slopes Summary for Lumbar Spine, Total Hip 
and Femoral Neck Bone Mineral Density (BMD) Adjusted by Age, BMI, and Race (Frequency Matching) 
a
 
Annual BMD Slopes Summary for Lumbar Spine, Total Hip and Femoral Neck BMD a 
 (95% Confidence interval) 
 Lumbar Spine Total Hip Femoral Neck 
Referent 
b
 -0.48% (-0.537%, -0.425%) -0.321% (-0.366%, -0.276%) -0.599% (-0.654%, -0.544%) 
Change from referent group 
c
 
ACE 0.185%   (+0.085%, +0.286%) 0.044% (-0.037%, +0.124%) -0.017% (-0.106%, 0.072%) 
Beta Blocker 0.162%   (+0.064%, +0.261%) -0.019% (-0.097%, +0.059%) 0.164% (0.076%, 0.251%) 
Thiazide 0.381%   (+0.281%, +0.481%) 0.229% (+0.149%, +0.310%) 0.375% (0.284%, 0.466%) 
BMI (kg/m2) 
c
 0.067% (+0.057%, +0.077%) 0.052% (+0.044%, +0.060%) 0.079 (0.069%, 0.089%) 
Raced    
Black -0.662% (-0.828%,-0.496%) -0.600% (-0.733%, -0.468%) -0.347% (-0.517%, -0.177%) 
Other 0.118% (-0.043%, +0.279%) 0.063% (-0.066%, +0.192%) 0.007% (-0.159%, 0.173%) 
Age (years) 
c
 -0.155% (-0.173%, -0.138%) -0.161% (-0.175%,-0.147%) -0.139% (-0.157%, -0.121%) 
a
 In addition to the variables listed, the model is also adjusted for site, physical activity, total number of 
comorbidities, ever use hormone therapy, ever used diabetes related medications, ever used bisphosphonates, ever 
used antidepressants. Slope referent values are for white women of average age (53.77 years), average BMI 
(27.64kg/m2).                                                                                                                                                                    
b
 Slope referent values are for White nonusers.                                                                                                                
c
 To get slopes for Medications, BMI, Race and Age, number needs to be added to the white and nonuser slope 
referent values.                                                                                                                                                                  
d
 Statistically significant associations are shown in bold italic typeface. 
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4.4 MULTIVARIATE MIXED MODELS (PROPENSITY SCORE MATCHING) 
Due to the design of propensity score matching, models were created to compare each drug of 
interest with nonusers separately. In the models for each drug class (Table 9-11), results were 
similar to results of frequency matching. Compared to no antihypertensive use, neither ACE nor 
beta blocker use was significantly related to BMD loss at any measured sites (Table 9 and 10). 
Table 11 shows that thiazide significantly slowed down the lumbar spine BMD loss by 3.157% 
(p =0.05) and decelerated the femoral neck BMD loss by 3.387% (p =0.0112). Unlike previous 
results shown in Table 7, for thiazide users, the rate of bone loss at the total hip was not 
significantly decelerated (1.643%, p =0.16).  
The interaction between drug effect and menopause stage was tested for each pair 
comparison, and only the interaction between menopause status and thiazide on lumbar spine 
BMD loss was significant. This means that the effect of thiazide on lumbar spine BMD varied by 
the stage of menopause. The thiazide effects during menopausal transition are summarized in 
Table 12. Thiazide use during the late and post menopause decreases the lumbar spine BMD loss 
by 0.491% (95% CI: 0.026%-0.956%) and 0.452% (95% CI: 0.040%, 0.864%), respectively. 
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Table 9: Adjusted Mixed Model for Lumbar Spine, Total Hip and Femoral Neck among ACE Users and Matched 
Nonusers (Propensity Score Matching) 
  Lumbar Spine Total Hip Femoral Neck 
Variable Coefficient P-value Coefficient P-value Coefficient P-value 
Intercept 98.860% <.0001 99.240% <.0001 97.710% <.0001 
  Medication Category             
    ACE (vs. Non) -0.015% 0.9707 -0.542% 0.1667 0.176% 0.7004 
  Pre-/Peri-menopause 0.606% 0.366 0.141% 0.8193 2.189% 0.0034 
  Late menopause -3.440% <.0001 -2.285% 0.0008 -1.427% 0.0853 
  Post menopause -2.993% <.0001 -1.805% 0.0107 -1.661% 0.0447 
Slope             
  Time 0.340% 0.2473 0.120% 0.6719 -0.311% 0.3191 
Slope             
    Time*ACE (vs. Non) 0.042% 0.7765 -0.185% 0.214 -0.099% 0.4872 
  Time*Pre-/Peri-
menopause 
-0.042% 0.8861 0.229% 0.4126 0.707% 0.0302 
  Time*Late menopause -1.317% <.0001 -0.628% 0.025 -0.510% 0.1039 
  Time*Post menopause -0.929% 0.0014 -0.539% 0.052 -0.441% 0.1517 
Demographics             
Age (center at 53.77) -0.046% 0.4431 -0.139% 0.0134 -0.078% 0.2535 
Ethinicity    0.1495   0.8985   0.5339 
  Black (vs. Caucasion) 0.335% 0.4856 0.125% 0.7793 0.188% 0.7365 
  Asian (vs. Caucasion) -1.225% 0.0635 -0.234% 0.7019 -0.813% 0.2778 
SITE   0.0043   0.0456   0.1796 
  UCDavis (vs. Pittsburgh) 1.731% 0.0159 0.877% 0.1872 -0.140% 0.8645 
  UCLA (vs. Pittsburgh) 1.935% 0.0058 -0.416% 0.5242 -1.001% 0.2155 
  Michigan (vs. Pittsburgh) 2.091% 0.0003 0.489% 0.3615 0.222% 0.7395 
  MGH (vs. Pittsburgh) 1.796% 0.0022 1.027% 0.0586 0.801% 0.2365 
BMI (center at 27.64) -0.044% 0.1953 -0.031% 0.3231 -0.005% 0.8884 
Total # of Comorbidities -0.099% 0.5599 0.101% 0.5209 0.290% 0.1295 
Physical Activity 0.048% 0.6739 0.065% 0.5416 0.041% 0.7502 
Other Medication Use             
  Ever Reported HT Use 0.152% 0.7618 0.190% 0.6816 -0.277% 0.6155 
  Diabetes Related Meds 0.328% 0.495 -0.534% 0.2303 -0.231% 0.6728 
  Bisphosphonates 0.978% 0.1975 1.746% 0.0132 0.016% 0.9849 
  Antidepressants -0.359% 0.3683 0.297% 0.4176 -0.066% 0.884 
Abbreviations: Non, Nonusers; #, number; Meds, Medications; Time, Time been on the drug.  
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Table 10: Adjusted Mixed Model for Lumbar Spine, Total Hip and Femoral Neck among Beta Blocker Users and 
Matched Nonusers (Propensity Score Matching) 
  Lumbar Spine Total Hip Femoral Neck 
Variable Coefficient P-value Coefficient P-value Coefficient P-value 
Intercept 99.390% <.0001 97.950% <.0001 100.290% <.0001 
  Medication Category             
    Beta Blocker (vs. Non) 0.688% 0.0843 0.554% 0.0415 1.189% 0.0003 
  Pre-/Peri-menopause 2.429% <.0001 1.471% 0.0004 0.857% 0.0968 
  Late menopause -0.334% 0.6107 0.057% 0.9033 -0.660% 0.2437 
  Post menopause -0.242% 0.6974 -0.992% 0.027 -1.194% 0.0311 
Slope             
  Time -0.650% 0.0058 -0.462% 0.0036 -0.683% 0.0003 
Slope             
    Time*BB (vs. Non) 0.042% 0.8325 -0.039% 0.72 0.223% 0.0775 
  Time*Pre/Peri menopause 0.775% 0.0001 0.433% 0.0056 0.686% 0.0004 
  Time*Late menopause -0.187% 0.3942 0.033% 0.8383 0.255% 0.1867 
  Time*Post menopause 0.027% 0.8997 -0.201% 0.1906 -0.200% 0.2833 
Demographics             
Age (center at 53.77) -0.011% 0.8234 -0.101% 0.0046 -0.177% <.0001 
Ethinicity    0.0006   0.0021   0.7632 
  Black (vs. Caucasion) -1.833% 0.0007 -1.261% 0.0004 -0.317% 0.4624 
  Asian (vs. Caucasion) 1.114% 0.0538 0.095% 0.8078 0.006% 0.9898 
SITE   0.0031   0.0009   0.001 
  UCDavis (vs. Pittsburgh) -1.876% 0.0104 -0.880% 0.0711 -2.071% 0.0005 
  UCLA (vs. Pittsburgh) -2.082% 0.002 -1.565% 0.0005 -1.383% 0.0123 
  Michigan (vs. Pittsburgh) 0.274% 0.6444 -0.979% 0.0147 -1.729% 0.0004 
  MGH (vs. Pittsburgh) -0.760% 0.2301 -1.539% 0.0002 -0.789% 0.1206 
BMI (center at 27.64) 0.044% 0.1437 0.028% 0.1873 0.035% 0.1684 
Total # of Comorbidities -0.264% 0.0957 0.184% 0.0873 0.008% 0.9502 
Physical Activity -0.064% 0.5081 0.100% 0.1486 -0.091% 0.2787 
Other Medication Use             
  Ever Reported HT Use 0.302% 0.5366 0.549% 0.1147 -0.313% 0.4613 
  Diabetes Related Meds -0.207% 0.7844 -0.729% 0.1976 0.779% 0.2538 
  Bisphosphonates 1.278% 0.1806 2.705% 0.0001 1.620% 0.0595 
  Antidepressants 0.269% 0.434 0.336% 0.2069 0.461% 0.1609 
Abbreviations: Non, Nonusers; BB, Beta Blocker; #, number; Meds, Medications; Time, Time been on the drug. 
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Table 11: Adjusted Mixed Model for Lumbar Spine, Total Hip and Femoral Neck among Thiazide Users and 
Matched Nonusers (Propensity Score Matching) 
  Lumbar Spine Total Hip Femoral Neck 
Variable Coefficient P-value Coefficient P-value Coefficient P-value 
Intercept 98.470% <.0001 99.300% <.0001 98.080% <.0001 
  Medication Category             
    Thiazide (vs. Non) 1.240% 0.0051 0.721% 0.0288 1.355% 0.0012 
  Pre-/Peri-menopause 0.272% 0.7621 1.460% 0.034 1.076% 0.2245 
  Late menopause -1.674% 0.0587 -0.458% 0.4757 0.073% 0.9293 
  Post menopause -0.414% 0.6085 -0.415% 0.5008 0.384% 0.6208 
Slope             
  Time -0.005% 0.9856 0.133% 0.5582 -0.552% 0.0588 
  Time*Medication              
    Time*Thiazide(vs. 
Non) 
0.316% 0.0466 0.164% 0.1638 0.339% 0.0112 
  Time*Pre/Peri 
menopause 
-0.296% 0.3388 0.085% 0.7228 0.160% 0.6165 
  Time*Late menopause -1.055% 0.0003 -0.604% 0.0071 -0.298% 0.3095 
  Time*Post menopause -0.648% 0.019 -0.664% 0.0021 -0.167% 0.5523 
Demographics             
Age (center at 53.77) -0.016% 0.7934 -0.148% 0.001 -0.120% 0.0382 
Ethinicity    0.0597   0.0067   0.0002 
  Black (vs. Caucasion) -0.816% 0.1077 -0.679% 0.0679 -1.079% 0.0283 
  Asian (vs. Caucasion) 1.034% 0.0976 1.171% 0.0127 2.146% 0.0006 
SITE   0.0095   0.106   <.0001 
  UCDavis (vs. Pittsburgh) -2.260% 0.0007 -0.628% 0.2064 -2.801% <.0001 
  UCLA (vs. Pittsburgh) -1.978% 0.0045 -1.344% 0.0104 -3.706% <.0001 
  Michigan (vs. Pittsburgh) -0.651% 0.3023 -0.348% 0.4522 -1.124% 0.0676 
  MGH (vs. Pittsburgh) -0.496% 0.3826 -0.059% 0.8881 -1.044% 0.0593 
BMI (center at 27.64) 0.192% <.0001 0.080% 0.0006 0.120% 0.0001 
Total # of Comorbidities -0.472% 0.0064 -0.218% 0.0939 -0.522% 0.0024 
Physical Activity 0.231% 0.0463 0.009% 0.9206 0.141% 0.2111 
Other Medication Use             
  Ever Reported HT Use -0.979% 0.1362 -0.027% 0.9561 0.744% 0.2137 
  Diabetes Related Meds -0.134% 0.8722 -1.244% 0.0499 0.652% 0.4213 
  Bisphosphonates -1.820% 0.1037 0.310% 0.7165 -0.492% 0.6485 
  Antidepressants -0.416% 0.4108 -0.797% 0.0398 0.077% 0.8807 
Abbreviations: Non, Nonusers; #, number; Meds, Medications; Time, Time been on the drug.  
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Table 12: Influence of Thiazide Use on Annual Rates of Change of Lumbar Spine Bone Mineral Density (BMD) by 
Menopause Status Adjusted by Age, BMI, and Race (Propensity Score Matching, 3-way interaction) 
a
  
Annual BMD Slopes Summary for Lumbar Spine by Menopause Status 
(95% Confidence interval) 
 Pre/Peri Menopause Late Menopause Post Menopause 
Referent 
b
 0.267% ( -0.495%, 1.029% ) -0.704% ( -1.415%, 0.007% ) -0.271% ( -0.947%, 0.405% ) 
Change from referent group 
c
 
Thiazide -0.164%(-0.851%, 0.524%) 0.491% (0.026%, 0.956%) 0.452% (0.040%, 0.864%) 
BMI (kg/m2) 
c
 -0.104% (-0.446%, 0.237%) -0.863% (-1.185%, -0.542%) -0.456% (-0.763%, -0.150%) 
Raced    
Black -1.112% (-1.928%, -0.296%) -1.871% (-2.667%, -1.075%) -1.464% (-2.245%, -0.683%) 
Other 0.738% (-0.194%, 1.670%) -0.021% (-0.934%, 0.892%) 0.386% (-0.512%, 1.284%) 
Age (years) 
c
 -0.312% (-0.681%, 0.057%) -1.071% (-1.421%, -0.721%) -0.664% (-0.999%, -0.329%) 
a
 In addition to the variables listed, the model is also adjusted for site, physical activity, total number of 
comorbidities, ever use hormone therapy, ever used diabetes related medications, ever used bisphosphonates, ever 
used antidepressants. Slope referent values are for white women of average age (53.77 years), average BMI 
(27.64kg/m2).                                                                                                                                                                      
b
 Slope referent values are for White nonusers.                                                                                                                
c
 To get slopes for Medications, BMI, Race and Age, number needs to be added to the white and nonuser slope 
referent values.                                                                                                                                                                  
d
 Statistically significant associations are shown in bold italic typeface.                                           
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5.0  DISCUSSION 
5.1 SUMMARY OF STUDY FINDINGS 
This study used two methods to examine the longitudinal relationship between antihypertensive 
medication (ACE, beta blocker and thiazide) use and changes in BMD at lumbar spine, total hip 
and femoral neck. The results shown by different models were generally consistent with each 
other. Thiazide showed a protective effect on lumbar spine, and femoral neck, and a marginal 
positive effect on total hip. In particular, use of thiazide during late and postmenopause had a 
positive effect on the lumbar spine BMD. The results for ACE and beta blocker were consistent 
and showed no association with BMD loss at any of the sites. 
 Thiazide diuretics were found to have a protective effect on femoral neck, total hip and 
lumbar spine BMD loss among the women who were prescribed thiazide diuretics to treat 
hypertension. Although in the randomized controlled trials (presented in Chapter 1.2.4), the 
results generally tend to be similar with the results in this paper, the results obtained from the 
RCT are regarding specific drug within thiazide diuretics category in normotensive women, 
rather than hypertensive women. In the observational studies
37,38,40
, bone sites, calcaneus, distal 
radius, and proximal radius, were prevalently under studied, but the BMD data collected for 
femoral neck, total hip and lumbar spine were rarely seen, to the author’s knowledge.  
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ACE was not found to affect BMD loss compared to nonuse and the result is consistent 
with the 1-year prospective cohort study reported by García-Testal et al
43
, with no significant 
relation between ACE and BMD loss. However, in a cross-sectional study invoving 1929 women 
(161 ACE users and 1768 nonuser), Lynn et al
42
 found that higher femoral neck BMD associated 
with ACE use compared to nonuse. However, in Lynn et al’s study, the combination use of drug 
(including ACE/thiazide and ACE/beta blocker) was not excluded and may contribute to the 
significant protective effect.  
The nonsignificant findings regarding beta blocker in this study are consistent with the 
findings in the Geelong Osteoporosis Study
45
 and Study of Osteoporotic Fracture
47
. In the Dubbo 
Osteoporosis Epidemiology Study
44
, baseline characteristics indicate that, in women, beta 
blocker users had significantly higher femoral neck BMD and lumbar spine BMD. However, this 
study used cross-sectional BMD value and could not evaluate the BMD loss over time. 
 Two potential mechanisms may explain these results. First, thiazide has an overall 
positive effect on BMD by inhibiting the Na
+
/Cl
-
 co-transporters in human osteoblast and 
osteoblast-like cells, thereafter enhancing bone calcium uptake. Second, one of the potential 
reasons that the protective effect for thiazide is not significant during the pre-/peri-menopause 
may be that serum follicle-stimulation hormone level is still low and the contribution of the 
thiazide towards BMD protection is not prominent compared to the hormone’s contribution. 
However, this explanation needs to be validated by further studies. Another potential reason is 
that there is no significant BMD loss during pre-/peri menopause regardless of drug use.
13
 On the 
basis of the fact that use of thiazide does not increase BMD value, we may form the hypotheses 
that thiazide either interact with the nature bone metabolism indirectly or inhibit the targets 
competing with another biological component. 
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5.2 CONTRIBUTION TO THE LITERATURE 
The results from this study agreed with and expanded previous research. Previous studies mainly 
focused on BMD change over two cross-sectional time point or the cumulative change over time. 
In contrast to previous studies, this study used standardized annually collected data for women 
across the menopause and has validated menopause status retrospectively. Because of the study 
design of SWAN, this secondary analysis can differentiate drug effect in each menopause status, 
which has not been published elsewhere. Moreover, this study was rigidly designed and the 
results were cross validated by two methods (frequency matching and propensity score 
matching).  
A large body of literature has reported association between fracture risk and 
antihypertensive drugs, but without any BMD data. Outcomes of this study can be used to 
support the role of BMD loss in terms of fracture. This analysis has many advantages over 
existing work, with a focus on an age group of women that was not often covered by other 
literature. This study also captured the extent to which BMD loss in the menopausal transition 
may be slowed down due to the use of thiazide diuretics. 
This study also examined the long term BMD loss after initiating antihypertensive 
therapy. It enabled us to quantify the effect over approximately 7.5 (±3.6) years; double the 
length of follow-up time of the randomized controlled trials published so far.
39
 It is difficult and 
expensive to conduct a randomized clinical trial with the long follow-up time required for a trial 
to have sufficient power to observe differences. Moreover, to accrue BMD related endpoint is 
often too expensive to make it feasible. Thus, the alternate option to estimate the causal effect is 
to use propensity score analyses. This study used propensity score matching to minimize the 
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differences of characteristics at the baseline between groups in order to ensure the 
exchangeability and positivity, which was rarely used in previous literature regarding this topic. 
5.3 STUDY LIMITATIONS AND FUTURE RESEARCH 
Study limitations are listed below, mainly including concern of overt bias, optimal matching, 
cofounding by indication. The imbalances of characteristics between groups prior to treatment 
were shown in Table 3, causing concern of overt bias that may have affected the conclusion draw 
from Chapter 4.3. Overt bias is defined as the treated and control groups differ prior to treatment 
in ways that matter for the outcomes under studied. Although overt bias is common in the 
observational studies and it may not lead to substantially different conclusions, overt bias still 
creates problems in distinguishing whether the outcome associates with the drug use or the 
conditions that lead to the drug use. In this study, we used the new user design to limit this bias 
by excluding the prevalent users at the SWAN study baseline, who may have more severe 
hypertension compared to the new users. We also used propensity score matching to verify the 
conclusion.  
The tradeoff of using propensity score matching (optimal matching) is that some women 
in the treatment groups may be excluded due to incomplete matches, which reduces statistical 
power. Incomplete matches may result due to two reasons: missing data of the covariates when 
multivariate analysis is used to calculate the propensity score or not enough overlap in propensity 
scores between treatment group and control group.
63
 After the propensity score matching, there 
are still 69 women in the ACE group, 88 in the beta blocker group and 76 in the thiazide group, 
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as compared to the original identified 98, 107, and 99 respectively. Similar conclusions, drawn 
from the propensity score analysis and the frequency matching analysis, provided strong 
supportive evidence. 
Confounding by indication remains as a potential bias in this study, as it does in any other 
pharmacoepidemiology study.
64
 Blood pressure, in this study, is a time-varying confounder, 
which may be affected by the exposure and may also affect the BMD, and we did not count for 
this. Conditioning on blood pressure not only creates selection bias but also prevents 
identification of the total effect of the exposure to antihypertensive medication. However, blood 
pressure at baseline is used to estimate the propensity score, because it is associated with 
treatment selection.  
This study has a sub-cohort of women who were prescribed antihypertensive medications 
to treat hypertension symptoms and only included women across menopause, so the results 
cannot be generalized to men, to normotensive women, or to younger women who have not 
started the menopause transition. The population selected for this analysis does not stand for 
overall SWAN population; therefore, the annualized rate of the BMD loss presented here is not 
comparable with the annualized BMD loss rate for the overall SWAN population. Drug dosage 
information for exploring dose-event relationships is not available. 
Future research can be done to answer the following questions. Firstly, future research is 
needed to understand the mediators of thiazide’s protective effect on BMD loss. Thiazide leads 
to the varied effect on BMD loss during each menopausal period whether or not thiazide 
interacts with other biological changes (e.g. the level of serum follicle-stimulation hormone). 
Secondly, the safety of thiazide use among normotensive women needs to be further evaluated 
for osteoporosis prevention in healthy women during the menopause transition. Thirdly, whether 
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the reduced BMD loss was due to controlled blood pressure or the drug itself remains as 
questions that need to be answered. In the end, future research should be done to validate 
thiazide’s protective effect on the BMD loss when used as an add-on therapy to other 
antihypertensive medications, because two or more agents from different pharmacologic classes 
are often needed to achieve adequate blood pressure control. 
5.4 PUBLIC HEALTH SIGNIFICANCE  
The findings in this study provided reassurance for women who were using ACE or BB to 
control blood pressure during the menopause transition, because neither of them has any negative 
effect on BMD loss during the transition. The results of this study also encourage clinicians to 
integrate the benefits of using thiazide diuretics, from the prospective of protecting the bone loss, 
into patients’ education, especially for women during late- or post-menopause if there are no 
other contraindications. 
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APPENDIX A 
GLOSSARY OF ABBREVIATIONS 
The following terms are listed alphabetically: 
ACE--angiotensin-converting enzyme inhibitors 
BB--beta blocker 
BMD--bone mineral density 
BMI--body mass index 
CES-D--center for epidemiologic studies depression scale 
FMP--final menstrual period  
GERD--Gastroesophageal Reflux Disease 
HT-- hormone therapy 
IDIS--Iowa Drug Information System  
RAAS--renin-angiotensin-aldosterone system 
SWAN--Study of Women's Health Across the Nation 
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APPENDIX B 
MODELING STRATEGY 
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